Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Equity Ratio (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Equity Ratio for 4 consecutive years, with 1.69 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 152.25% to 1.69 in Q4 2025 year-over-year; TTM through Dec 2025 was 1.69, a 152.25% decrease, with the full-year FY2025 number at 1.69, down 152.25% from a year prior.
  • Equity Ratio was 1.69 for Q4 2025 at Phathom Pharmaceuticals, up from 1.76 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.26 in Q1 2022 to a low of 1.76 in Q3 2025.
  • A 4-year average of 0.61 and a median of 0.47 in 2024 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: surged 302.54% in 2023, then plummeted 1202.54% in 2024.
  • Phathom Pharmaceuticals' Equity Ratio stood at 0.45 in 2022, then skyrocketed by 61.27% to 0.18 in 2023, then tumbled by 281.25% to 0.67 in 2024, then crashed by 152.25% to 1.69 in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Equity Ratio are 1.69 (Q4 2025), 1.76 (Q3 2025), and 1.62 (Q2 2025).